Combination strategies in the treatment of Melanoma
For many years melanoma was considered a significant challenge by oncologists. In 2011 the story changed because of the approval of ipilimumab, an anti-CTLA4 monoclonal antibody, and vemurafenib, a BRAF inhibitor active on BRAF mutated melanoma. These two revolutionary drugs completely changed the management of metastatic melanoma and, for the first time, became possible to achieve a significative impact on overall survival. To improve the efficacy of ipilimumab and vemurafenib have been designed clinical trials, now ongoing, of combination with other targeted agents (e.g. MEK inhibitors) and immunotherapeutic compounds (e.g. anti-PD-L1). Other possible combinations of these two new drugs can be in association with surgery, radiotherapy and/or chemotherapy. However, new targeted drugs combination or a sequence of combined therapies represent the future treatment not only for melanoma, but for about all solid tumors.
How we work:
- After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
- A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
- Author proof is generated within 7 working days after the acceptance decision.
Benefits on Publication:
Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.
Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.
Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.
Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.
Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.
Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.
Journal of Clinical & Experimental Dermatology Research